Results 241 to 250 of about 21,216 (279)

Hepatic steatosis associated with exposure to elvitegravir and raltegravir.

Clinical Infectious Diseases, 2021
Moderate-to-severe hepatic steatosis in people living with HIV without viral hepatitis or excessive alcohol intake was associated with cumulative exposure to stavudine, elvitegravir and raltegravir.
D. Kirkegaard-Klitbo, M. T. Thomsen, M. Gelpi, F. Bendtsen, S. Nielsen, T. Benfield   +5 more
semanticscholar   +1 more source

Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trial

HIV Medicine, 2021
Persistent inflammation and immune activation are associated with lymph node fibrosis and end‐organ diseases in treatment‐suppressed people living with HIV (PLWH).
B. Torres, A. Guardo, M. Squarcia, A. Díaz, A. Fabra, M. Caballero, A. Ugarte, L. Leal, JM Gatell, M. Plana, F. Garcia   +10 more
semanticscholar   +1 more source

Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s

Clinical Infectious Diseases, 2016
Grace A Mccomsey, Carlee Moser, Theodoros Kelesidis   +2 more
exaly   +2 more sources

Seeking for Selectivity and Efficiency: New Approaches in the Synthesis of Raltegravir

, 2020
The present work describes the development of an improved synthesis of active pharmaceutical ingredient raltegravir.
F. Caputo, S. Corbetta, O. Piccolo, D. Vigo   +3 more
semanticscholar   +1 more source

Raltegravir

Reactions Weekly, 2017
  +10 more sources

Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapy.

Journal of Antimicrobial Chemotherapy, 2020
BACKGROUND Antiretroviral dual regimens including lamivudine and one boosted PI or dolutegravir are warranted in order to optimize combination ART (cART), prevent long-term toxicity and reduce the cost of treatments.
L. Calza, V. Colangeli, M. Borderi, Diletta Testi, B. Granozzi, I. Bon, M. Re, P. Viale   +7 more
semanticscholar   +1 more source

Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease

Infectious Diseases, 2019
Background: The ritonavir-boosted protease inhibitor (PI/r) use has been associated with several metabolic abnormalities, and the non-alcoholic fatty liver disease (NAFLD) is becoming a very frequent comorbidity among HIV-infected patients.
L. Calza, V. Colangeli, M. Borderi, Simona Coladonato, Beatrice Tazza, Giacomo Fornaro, L. Badia, Viola Guardigni, G. Verucchi, P. Viale   +9 more
semanticscholar   +1 more source

Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients

Journal of Antimicrobial Chemotherapy, 2018
OBJECTIVES An observational, prospective, cohort study was performed to assess changes in insulin sensitivity and serum leptin level after a switch from a ritonavir-boosted PI (PI/r) to raltegravir or dolutegravir in HIV-infected adults on stable ...
L. Calza, V. Colangeli, M. Borderi, Simona Coladonato, Beatrice Tazza, I. Bon, M. Re, P. Viale   +7 more
semanticscholar   +1 more source

Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir

Journal of Antimicrobial Chemotherapy, 2018
BACKGROUND Elbasvir/grazoprevir is a once-daily fixed-dose combination therapy for the treatment of chronic HCV infection, including HCV/HIV coinfection.
Hwa-ping Feng, Zifang Guo, L. Ross, Iain P. Fraser, D. Panebianco, Patricia A. Jumes, Christine M. Fandozzi, L. Caro, J. Talaty, Joanne Ma, E. Mangin, Xiaobi Huang, W. Marshall, J. Butterton, Marian Iwamoto, W. Yeh   +15 more
semanticscholar   +1 more source

Raltegravir

Reactions Weekly, 2015
  +6 more sources